LEXI® is a Non-Invasive Prenatal Diagnostic (NIPD) in development that isolates fetal cells in maternal blood for the definitive analyses of over thousands of conditions in the fetus.

Current Non-Invasive Prenatal Test (NIPT) utilise fragmented circulating cell-free fetal DNA (cffDNA) in pregnant women, and makes inferences from the maternal blood.

However, fetal cells in maternal blood represent the Holy Grail of prenatal diagnosis. The major challenge has been isolation of these cells from maternal blood owing to their rarity.

INEX's Solution

Major advances have been made by INEX team in the field of non-invasive Prenatal Diagnosis (NIPD), to isolate, recognise and analyse the fetal cells derived from maternal blood. INEX is developing a Non-Invasive Prenatal Diagnostic (NIPD) test based on a patented methodology of isolating fetal cells in maternal blood called LEXI®.


LEXI has the potential to detect of more than 7,000 genetic conditions


The test results can be clinically used to improve personalized medicine treatment strategies with potential applications in research and development of new drugs and therapies.

  1. Albert, H., 2017. A Noninvasive Future: Prenatal Genetic Testing Looks to Single-Cell Methods as the Next Frontier. Clinical OMICs4(4), pp.20-22.

LEXI® is under development.


If you're interested in LEXI® and would like to know more or partner with us, let's chat.